Premier US healthcare improvement company to offer Bioventus’ full surgical portfolio

Bioventus’ full surgical portfolio

Bioventus has announced that its full surgical orthobiologics portfolio is now available through Premier, a US health care improvement company comprised of 3,750 US hospitals and more than 130,000 other provider organisations throughout the country.

Bioventus Surgical offers a platform of allograft bone, synthetic bone graft substitutes and cell and marrow extraction needles.

Osteoamp—an allograft fusion solution—has been available through Premier since 2012. Additional products in the new agreement include: Signafuse bioactive bone graft substitute; Exponent demineralised bone matrix, Purebone demineralised cancellous bone and cancellous chips, Interface bioactive bone graft,  Osteomatrix biphasic mineral/collagen bone graft, Osteoplus biphasic mineral bone graft, Cellxtract autologous cell and marrow extraction device, and Extractor autologous cell and marrow extraction device.


Please enter your comment!
Please enter your name here